Diversity – at least among cancer cells – is not a good thing. Now, research from the Weizmann Institute of Science shows that in melanoma, tumors with cells that have differentiated into more diverse subtypes are less likely to be affected by the immune system, thus reducing the chance that immunotherapy will be effective.